- Details
- Sean Sachdev and Praneet Polineni delve into their paper on trimodality therapy for muscle-invasive bladder cancer. Dr. Sachdev highlights the growing evidence supporting trimodality therapy as a viable option, especially for older patients who may not be good candidates for surgical intervention. Dr. Polineni offers details on their study, which involved 32 patients with a mean age of 73. The tre...
|
- Details
- Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities. Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible pat...
|
- Details
- Several Phase III trials have read out in the first-line treatment of metastatic urothelial cancer in the past few years. In a discussion with Ashish Kamat, Matthew Galsky discusses the expanse in clinical data in metastatic urothelial cancer shaping the treatment landscape. Guiding this conversation, Matthew Galsky focuses on 4 main take-home points and shares optimism in potential development to...
|
- Details
- Alicia Morgans hosts a discussion with Neeraj Agarwal and Petros Grivas about the FDA's approval of sacituzumab govitecan for treating metastatic urothelial carcinoma. Dr. Grivas elaborates on the TROPHY-U-01 trial that led to the drug's approval, emphasizing its efficacy in a heavily pretreated patient population with poor prognostic factors. He notes an overall response rate of 27% and manageabl...
|
- Details
- A transurethral resection of bladder tumor (TURBT), followed by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) is a standard-of-care therapy for muscle-invasive bladder cancer (MIBC). Andrea Necchi, a medical oncologist, and Ewan Gibb a researcher at Decipher Biosciences join Alicia Morgans to discuss a study that expands our understanding of the biology of pembrolizumab-resistant musc...
|
- Details
- Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors also express PD-L1. Patients who are ineligible for cisplatin and progress on immune checkpoint blockade have limited treatment options, and many efforts are underway to expand the therapeutic armamentarium for this disease context. In this conversation...
|
- Details
- Alicia Morgans talks with Andrea Necchi and Laura Marandino. They delve into the PURE-01 study, which focuses on the use of neoadjuvant pembrolizumab in muscle-invasive bladder cancer patients. Dr. Necchi elaborates on the study's primary and secondary endpoints and highlights the role of PET-CT imaging in assessing treatment response. The study finds that PET-CT has limited utility in predicting...
|
- Details
- Platinum-based cytotoxic chemotherapy has been the standard of care for patients with advanced urothelial carcinoma based on improved survival compared to placebo. However, objective response rates are at best 50% and median overall survival is relatively poor at less than 18 months. This has driven the rationale for additional approaches. In first-line (1L) therapy for patients who are not cispla...
|
- Details
- Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (Trodelvy) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown pr...
|
- Details
- Alicia Morgans speaks with Petros Grivas to discuss the intricacies of the SWOG 1806 clinical trial, led by Dr. Parminder Singh. This multi-institutional study aims to evaluate the efficacy of adding atezolizumab, an anti-PD-L1 agent, to chemoradiation treatment in patients with localized muscle-invasive urothelial carcinoma. Dr. Grivas emphasizes the collaborative nature of this "Herculean effort...
|
